Basecamp Wealth Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History

Basecamp Wealth Advisors’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-128	Closed	-$5.08K	–	1861
2026 Q1	$5.08K	Hold	128	–	–	﹤0.01%	1178
2025 Q4	$3.2K	Buy	+128	New	+$3.24K	﹤0.01%	1258

Basecamp Wealth Advisors's CNTA Position: Q2 2026 in Review

Basecamp Wealth Advisors sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 128 shares — an estimated $5.08K sold.

Basecamp Wealth Advisors first reported a position in CNTA in Q4 2025 and held it in 2 quarters. The position peaked at $5.08K in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Basecamp Wealth Advisors reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Basecamp Wealth Advisors sold 128 Centessa Pharmaceuticals shares in Q2 2026, an estimated $5.08K.
Basecamp Wealth Advisors first reported a position in Centessa Pharmaceuticals in Q4 2025 and held it in 2 quarters.
Basecamp Wealth Advisors's Centessa Pharmaceuticals position peaked at $5.08K in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.